Log In Get Started
Press Releases May 13, 2026 04:15 PM

Dillard’s, Inc. to Report First Quarter Results

Dillard's to Announce First Quarter 2026 Financial Results

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
DDS

Dillard's, Inc. is scheduled to release its first quarter 2026 earnings results for the 13-week period ended May 2, 2026, before the NYSE opens. The announcement date is May 14, 2026.

Dillard’s, Inc. to Report First Quarter Results
DDS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Dillard's will report first quarter financial results for 2026.
  • The reporting period covers the 13 weeks ended May 2, 2026.
  • Results will be announced before the NYSE opens on May 14, 2026.

LITTLE ROCK, Ark., May 13, 2026 (GLOBE NEWSWIRE) -- Dillard’s, Inc. (DDS: NYSE) will announce results for the 13 weeks ended May 2, 2026 tomorrow before the open of the New York Stock Exchange.

Contact: Julie J. Guymon
Director of Investor Relations
(501) 376-5965         
julie.guymon@dillards.com


Risks

  • The announcement could show weaker than expected retail sales impacting stock price.
  • Changes in consumer spending and economic conditions may affect performance.
  • Market volatility around earnings release may affect stock price temporarily.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026